Presented by


Event sponsors

McKesson McKesson

Agency partners

Enterprise Ireland Enterprise Ireland
IDA Ireland IDA Ireland
InterTrade Ireland InterTrade Ireland
Science Foundation Ireland Science Foundation Ireland

Day 2 Plenary Session

Registration with light refreshments
Session one: Partnerships for unlocking the value of innovation
Simon Coveney TD, Tánaiste and Minister for Foreign Affairs and Trade
Ireland: towards a globally networked bio-innovation hub
The promise of academic-industry-government partnerships: unlocking the power of data to deliver fair value for all
Professor Mark Lawler, Associate Pro-Vice-Chancellor and Professor of Digital Health in the Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast
Lightning presentation: SoluporeŽ, next-generation cell engineering platform
Michael Maguire, Chief Executive, Avectas
The convergence of technology and life sciences
Jim O’Donoghue, President, S3 Connected Health
The changing paradigm: regulators as enablers
Dr Lorraine Nolan, Chief Executive, HPRA
Panel discussion
Networking break
Lightning Presentation: Targeting the NLRP3 Inflammasome to treat inflammatory diseases
Jeremy Skillington, Vice President, Business Development, Inflazome
Session 2: Thematic presentations and moderated discussions
Connected health
These presentations and the discussion explore the convergence of software, technology, data and processes in generating better insights about diseases and how they can be treated, how medicines can be evaluated and funded, and how treatments can be better tailored to meet clinical needs. In particular, we will explore how evidence based therapeutic interventions, driven by innovation and improvements in technology, can yield better health outcomes for patients.

Chaired by Denis O’Driscoll, Superintendent Pharmacist for LloydsPharmacy Ireland, McKesson Ireland
- Hannes Toivane, Lead for Strategic Partnerships, Centre of Excellence for Innovation Nordics, Takeda
- Joe Keenan, Global Digital Health Solutions Director, Novartis
- Joan Byrne, Vice President, Science and Technology, Drug and Device, AbbVie
- Arup K. Roy, Vice President, BioProduct Research and Development, Eli Lilly
Panel discussion
Networking lunch
Factory 4.0: The new manufacturing sites
The traditional ‘factory floor’ is changing at pace. Machine learning, robotics, artificial intelligence, blockchain, big data and the internet of things are all causing a shift from a human-based ecosystem to a machine-driven digital one. These presentations and the discussion examine how digitalisation is transforming manufacturing sites and product process lifecycles. We will try to capture the impact of the fourth industrial revolution, or 4IR, on the biopharmaceutical industry, with a particular focus on the opportunities for Ireland in a global context.

Chaired by Ian Jones, Founder and CEO, Innopharma Group
- Kieran Sheridan, Director, Global Manufacturing Systems, Alexion
- Ruth Beadle, Head of Vials Liquid/Lyo and Biologics Technology Group, Sanofi
- Alan Shefflin, Head, Digital Capability Management, Bristol-Myers Squibb
Panel discussion
Networking break
Future-fitting biopharma for best societal impact
These presentations and the discussion, chaired by PwC, explore the operating environment for biopharmaceutical innovators, drawing on experts’ analyses to identify improvement pathways across the medicines lifecycle. We will seek to sight opportunities to scale the industry in Ireland, especially in the area of advanced therapy medicinal products, with all actors, especially industry and the State, working together to maximise value in human health, in communities and in science.

Chaired by Shane Gannon, Director and the Sector Lead, Pharmaceuticals and Life Science Consulting, PwC Ireland
- Gary Hartnett, General Manager, Janssen Ireland Supply Chain
- Ian Winburn, Global Medical Lead Haemophilia, Endocrine and IEM, Pfizer Biopharmaceuticals Group
- Robert Grundy, Interim CEO, Health Innovation Research Alliance Northern Ireland
Panel discussion
Ireland: An island at the centre of the biopharma world
The Hon. James C. Greenwood, President and CEO, BIO
Conference close